Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients

• Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.

Detalles Bibliográficos
Autores principales: Graul, Ashley, Wilson, Elise, Ko, Emily, Haggerty, Ashley F., Reed, Helen, Koelper, Nathanael, Kim, Sarah H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148728/
https://www.ncbi.nlm.nih.gov/pubmed/30255125
http://dx.doi.org/10.1016/j.gore.2018.09.001
Descripción
Sumario:• Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.

Ejemplares similares